NCT05940896 is a Phase 1 clinical trial of Disitamab vedotin in Solid Tumor, sponsored by RemeGen Co., Ltd..

Who is sponsoring NCT05940896?

NCT05940896 is sponsored by RemeGen Co., Ltd..

What drugs are being tested in NCT05940896?

Interventions in NCT05940896: Disitamab vedotin.

What condition does NCT05940896 study?

NCT05940896 studies Solid Tumor.

Is NCT05940896 still recruiting?

NCT05940896 is currently recruiting now. Last updated 27 November 2023.

Last reviewed 2023-11-27 · How we verify

NCT05940896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Recruiting now Phase 1 Last updated 27 November 2023

What this trial tests

Phase 1 trial testing Disitamab vedotin in Solid Tumor in 24 participants. Currently enrolling.

Timeline

29 June 2023

Primary endpoint
16 November 2024

28 February 2027

Quick facts

Lead sponsor	RemeGen Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	29 June 2023
Primary completion	16 November 2024
Estimated completion	28 February 2027
Sites	1 location across China

Drugs / interventions tested

Disitamab vedotin (disitamab-vedotin) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

RemeGen Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the treatment of locally advanced solid tumors with HER2 expression

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations.
Lami I, Wiemer AJ. · · 2024 · cited 2× · PMID 38951479 · DOI 10.1007/s40268-024-00473-7

Verify or expand the search:

Other trials of Disitamab vedotin

Trials testing the same drug.

NCT06966453 — A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06904573 — Probiotics in Advanced Urothelial Carcinoma · Phase 2 · recruiting
NCT05904964 — Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) · Phase 3 · recruiting
NCT05586061 — First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer · Phase 2 · active not recruiting
NCT05333809 — Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer · Phase 2 · unknown

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other RemeGen Co., Ltd. trials

Trials by the same sponsor.

NCT07537881 — A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07462143 — A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT07495033 — Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related I · Phase 3 · not yet recruiting
NCT07416474 — RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Smal · Phase 3 · not yet recruiting
NCT07249632 — A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05940896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RemeGen Co., Ltd.
Last refreshed: 27 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05940896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing